Business
Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference
Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical models Anti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironment LUND, SWEDEN / ACCESS Newswire / April 25, ...
About this update from Cantargia Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical models","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Anti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironment","length":102,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":203,"olType":false},{"type":"text","content":"LUND, SWEDEN / ACCESS Newswire / April 25, 2025 / Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today released a poster with new preclinical data that strengthens the rationale behind the development of novel anti-IL1RAP ADCs. The current study shows the potential of interleukin-1 receptor accessory protein (IL1RAP) as a target for ADC therapy across a broad spectrum of cancers.The poster is presented at the American Association for Cancer Research (AACR) Annual Meeting.","length":479,"tagName":"p"},{"type":"text","content":""IL1RAP is an attractive target from an ADC perspective and the data presented show that conjugation of a toxic payload to an anti-IL1RAP antibody has strong potential as a safe and effective anti-tumor therapeutic. In addition, these data illustrate the strength of Cantargia's CANxx platform which contains numerous antibodies with different properties that can be developed into new IL1RAP-based therapies", said David Liberg, Chief Scientific Officer of Cantargia.","length":482,"tagName":"p"},{"type":"text","content":"An anti-IL1RAP ADC was generated from an antibody selected from Cantargia's unique library of IL1RAP-targeting antibodies and conjugated to a tubulin-targeting payload using ImmunoGen (now part of AbbVie) proprietary technology. More background information can be found in the press release issued on March 25, 2025 on the AACR abstract release.","length":349,"tagName":"p"},{"type":"text","content":"Preclinical data on the novel anti-IL1RAP ADC shows effective tumor growth inhibition with potent dose-dependent anti-tumor activity in a high IL1RAP expressing tumor model. Notably, a single dose of the ADC led to long-lasting efficacy, demonstrating 100% survival by day 95 in the high target expression model, compared to 60% in animals treated with a control ADC (non-targeting antibody conjugated to the same linker-payload). Strong tumor growth inhibition could ...